Journal Club

More Than Hair Loss: Understanding the Role the Immune System Plays in Developing Alopecia Areata and Its Treatment Implications

Launch Date
06/16/2022
Credit Amount
0.5 Hours
Credit Expires
06/20/2023
This activity is part of a series

Faculty

Emma Guttman-Yassky, MD, PhD
Waldman Professor and System Chair, The Kimberly and Eric J. Waldman Department of Dermatology
Director, Center of Excellence in Eczema, Director, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY
Emma Guttman-Yassky, MD, PhD

Emma Guttman-Yassky, MD, PhD is the system chair of the department of dermatology, and the Waldman Professor of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai, New York. She is the Director of the Center of Excellence in Eczema and the Laboratory for Inflammatory Skin Diseases. She earned her M.D. from Sackler School of Medicine at the Tel-Aviv University, and a Ph.D. degree from the Bar-Ilan University, Israel. After her Israeli Board certification in dermatology in Israel, Dr. Guttman moved to the U.S. to pursue a two-year postdoctoral fellowship at The Rockefeller University in the Laboratory for Investigative Dermatology. Upon completion of her fellowship, she became board-certified by the American Board of dermatology after a second dermatology residency training at Weill- Cornell Medical College, in NY.

Dr. Guttman’s major research focus areas are atopic dermatitis (AD)/eczema and alopecia areata. Her research made paradigm-shifting discoveries on the immunologic basis of AD/eczema in adults and children with atopic dermatitis, enriching the understanding of the pathophysiology of this common disorder, opening the door for novel, pathway-specific drugs in this disease. Recently, Dr. Guttman extended her research interest to hair loss disorders such as alopecia areata and scarring hair loss disorders, chronic hand eczema, keloids, ichtyosis, and other skin diseases, in which her findings are also translated to novel therapeutics.

Dr. Guttman co-founded the International Eczema Council (IEC), and is its immediate past president. Dr. Guttman received many national and international awards (e.g the AAAAI Award for Scientific Innovation and for pioneering discoveries, AAD Young Investigator award, etc). She was elected as a member to the American Society for Clinical Investigation/ASCI, and the American Dermatological Society/ADA. Dr. Guttman is often a keynote and plenary speaker in international and national meetings, and authored over 275 peer-reviewed publications.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Alopecia areata (AA) is a type of non-scarring hair loss. While the exact cause is not fully understood, new insights in disease understanding suggest an autoimmune pathology. The inflammatory pathways associated with AA destroy most of the hair follicle but spare the upper portion, giving rise to the possibility of hair regrowth and new targeted treatments that may improve patient outcomes. Therefore, staying up to date on current and emerging data for AA treatments is necessary to enhance comprehension of AA pathophysiology, assess patients, and inform potential treatment targets.

In the first installment of this three-part virtual Journal Club series, More Than Hair Loss: Understanding the Role the Immune System Plays in Developing Alopecia Areata and Its Treatment Implications, Dr. Emma Guttman-Yassky will present up-to-date information on the pathophysiology and specific immunologic pathways that affect AA.

Learning Objectives

At the end of this CME/CE activity, participants should be able to outline the pathophysiology of AA.

Financial Support

Supported by an educational grant from Pfizer Inc.

Target Audience

Physicians, PAs, and nurse practitioners specializing in dermatology, allergy/immunology, general practice, and/or pediatrics located outside of the United States

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hour.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

EACCME®

Through a mutual recognition agreement between the AMA and the UEMS-EACCME®, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

Qatar

Through a mutual recognition agreement between the AMA and the DHP, physicians licensed in Qatar completing an activity from a US-based ACCME-accredited CME provider can use ACCME AMA PRA Category 1 Credits™ toward their credit requirements.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

it is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Guttman-Yassky reports the following financial relationships:

Consultant: AbbVie Inc; Almirall; Amgen Inc.; Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; ASLAN Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Cara Therapeutics; Celgene Corporation; Connect Biopharma; Eli Lilly and Company; EMD Serono; Evidera; Galderma; Ichnos Sciences Inc.; Incyte; Janssen Biotech, Inc.; Kyowa Hakko Kirin Co., Ltd; LEO Pharma Inc.; Pandion Therapeutics; Pfizer Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; SATO Pharmaceutical, Co., Ltd; Siolta Therapeutics; Target PharmaSolutions, Inc.; UCB, Inc.; and Ventyx Biosciences, Inc.

Grants (Paid to Icahn School of Medicine at Mount Sinai): AbbVie Inc; Almirall; Amgen Inc.; AnaptysBio, Inc.; Asana BioSciences, LLC; AstraZeneca; Boehringer Ingelheim; Cara Therapeutics; Celgene Corporation; Eli Lilly and Company; Galderma; Glenmark Pharmaceutical Inc./Ichnos Sciences Inc.; Innovaderm; Janssen Pharmaceuticals, Inc.; Kao Corporation; Kiniksa Pharmaceuticals; Kyowa Hakko Kirin Co., Ltd; LEO Pharma Inc.; Novan, Inc.; Novartis; Pfizer Inc.; Ralexar Therapeutics, Inc.; Regeneron Pharmaceuticals Inc; and UCB, Inc.

Research Support (Paid to Icahn School of Medicine at Mount Sinai): AbbVie Inc; Almirall; Amgen Inc.; AnaptysBio, Inc.; Asana BioSciences, LLC; AstraZeneca; Boehringer Ingelheim; Cara Therapeutics; Celgene Corporation; Eli Lilly and Company; Galderma; Glenmark Pharmaceutical Inc./Ichnos Sciences Inc.; Innovaderm; Janssen Biotech, Inc.; Kao Corporation; Kiniksa Pharmaceuticals; Kyowa Hakko Kirin Co., Ltd; LEO Pharma Inc.; Novan, Inc.; Novartis; Pfizer Inc.; Ralexar Therapeutics, Inc.; Regeneron Pharmaceuticals Inc; and UCB, Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

  • Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • Kellie Busby, PharmD (planning committee)
  • Susan Perry (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

This activity is also offered in Podcast and Webcast formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

 

 

JC-022-061622-02

Activities in the Series

Immunodeficiency Disorders
06/16/2022

More Than Hair Loss: Understanding the Role the Immune System Plays in Developing Alopecia Areata and Its Treatment Implications

0.5 Hours
Begin Learn More
Dermatology
06/16/2022

More Than Hair Loss: Current and Emerging Therapies for Alopecia Areata

0.5 Hours
Begin Learn More
Immunodeficiency Disorders
06/16/2022

More Than Hair Loss: Global Perspectives on the Clinical Diagnosis and Management of Alopecia Areata

0.5 Hours
Begin Learn More
More Than Hair Loss: Understanding the Role the Immune System Plays in Developing Alopecia Areata and Its Treatment Implications
Event Date: 06/16/2022
Begin